Preparation of Radiolabeled Zolbetuximab Targeting CLDN18.2 and Its Preliminary Evaluation for Potential Clinical Applications
Molecular Pharmaceutics · 05.08.2024 · 21 (8) · 3838-3847
DOI: 10.1021/acs.molpharmaceut.4c00122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 01.07.2024. Verfasst von Yang Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai 201800, China. Hauptthemen laut MEDLINE: Claudins. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 32 Literaturangaben. Gefördert von: Shanghai Vista Pharmaceutical Technology Co., Ltd., Shanghai Institute of Applied Physics, Chinese Academy of Sciences.
Abstract (Originalsprache)
Claudin18.2 (CLDN18.2), due to its high expression in various gastric cancer tissues, is considered an optimal target for antitumor drug molecules. In this study, we obtained the labeled compounds of [125I]I-zolbetuximab using the Iodogen method. Under the optimum labeling conditions, the molar activity of [125I]I-zolbetuximab was 1.75 × 102 GBq/μmol, and the labeling efficiency was more than 99%. The labeled compounds exhibited excellent in vitro stability in both phosphate buffer saline (PBS, pH = 7.4) and fetal bovine serum systems (FBS) (radiochemical purity >90% at 72 h). The uptake percentage of [125I]I-zolbetuximab in MKN45-CLDN18.2 cells is 24.69 ± 0.84% after 6 h. The saturation binding assay and specificity assay further demonstrated the high specificity of [125I]I-zolbetuximab for CLDN18.2. The long retention at the tumor site and rapid metabolic clearance at other organ sites of [125I]I-zolbetuximab were observed in small-animal SPECT-CT imaging. The same trend was also observed in the biodistribution study. Due to the excellent targeting ability of zolbetuximab for CLDN18.2, [125I]I-zolbetuximab exhibits strong specific binding and retention with cells and tumors highly expressing CLDN18.2. However, the balance between mAb's longer cycle time in vivo and targeting binding and retention ability should be intensively considered for using this kind of radiopharmaceutical in the diagnosis and treatment of CLDN18.2-positive gastric cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Institute of Applied Physics, Chinese Academy of Sciences, Shanghai 201800, China.
- University of Chinese Academy of Sciences, Beijing 100049, China.
- Shanghai Vista Pharmaceutical Technology Co., Ltd, Shanghai 201816, China.
- Shanghai Engineering Research Center of Organ Repair, School of Medicine, Shanghai University, Shanghai 200444, China.
Förderung
- Shanghai Vista Pharmaceutical Technology Co., Ltd.
- Shanghai Institute of Applied Physics, Chinese Academy of Sciences
Zitieren
APA
Wang, Y., Ma, L., Kuang, Z., Li, D., Yang, J., Liu, Y., Zhang, L., Li, Z., & Li, Q. (2024). Preparation of Radiolabeled Zolbetuximab Targeting CLDN18.2 and Its Preliminary Evaluation for Potential Clinical Applications. Molecular Pharmaceutics, 21(8), 3838-3847. https://doi.org/10.1021/acs.molpharmaceut.4c00122
Vancouver
Wang Y, Ma L, Kuang Z, Li D, Yang J, Liu Y, et al. Preparation of Radiolabeled Zolbetuximab Targeting CLDN18.2 and Its Preliminary Evaluation for Potential Clinical Applications. Molecular Pharmaceutics. 2024;21(8):3838-3847. doi:10.1021/acs.molpharmaceut.4c00122
BibTeX
@article{Wang2024,
author = {Wang, Yang and Ma, Lin and Kuang, Zijun and Li, Dengke and Yang, Jian and Liu, Yuxia and Zhang, Lan and Li, Zheng and Li, Qingnuan},
title = {Preparation of Radiolabeled Zolbetuximab Targeting CLDN18.2 and Its Preliminary Evaluation for Potential Clinical Applications},
journal = {Molecular Pharmaceutics},
year = {2024},
volume = {21},
number = {8},
pages = {3838--3847},
doi = {10.1021/acs.molpharmaceut.4c00122}
}
EUVIMED